Unusual Volume Buzzers: Cbeyond (NASDAQ:CBEY), Advanced Micro Devices (NYSE:AMD), Sarepta Therapeutics Inc (NASDAQ:SRPT), AstraZeneca (NYSE:AZN)



The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Cbeyond, Inc. (NASDAQ:CBEY) and other violations of state law by the board of directors of Cbeyond Inc. (NASDAQ:CBEY) relating to the proposed buyout of the Company by Birch Communications, Inc. (“Birch”). Cbeyond, Inc. (NASDAQ:CBEY) stock performance was 38.56% in last session and finished the day at $9.81. Traded volume was 12.17million shares in the last session and the average volume of the stock remained 222.13K shares. The beta of the stock remained 1.77. Cbeyond, Inc. (NASDAQ:CBEY) insider ownership is 4.70%.

Monday’s biggest gainer in the SV150 was Advanced Micro Devices Inc. (NYSE:AMD), with the Sunnyvale chipmaker roaring 11.7 percent higher to $4.12 in the first trading session since the company’s earnings report was released Thursday afternoon. Advanced Micro Devices, Inc. (NYSE:AMD) rose 11.65 percent to $4.12 Monday on volume of 102.65million shares. The intra-day range of the stock was $3.95 to $4.20. Advanced Micro Devices, Inc. (NYSE:AMD) has a market capitalization of $2.99billion.

Sarepta Therapeutics Inc (NASDAQ:SRPT) got some very good news this morning when the Food & Drug Administration reversed itself and agreed to consider Sarepta Therapeutics Inc (NASDAQ:SRPT)’s experimental drug for Duchenne muscular dystrophy for accelerated approval. Sarepta Therapeutics Inc (NASDAQ:SRPT)’s stock on Apr 21, 2014 reported a increase of 39.26% to the closing price of $33.98. Its fifty two weeks range is $12.12 -$55.61. The total market capitalization recorded $1.28billion. The overall volume in the last trading session was 13.11million shares. In its share capital, SRPT has 37.77million outstanding shares.

Merger and acquisition activity could provide a boost for sentiment in Europe on Tuesday with reports that Pfizer could launch another bid for fellow drug company AstraZeneca Plc (ADR) (NYSE:AZN). This comes after a reported £60 billion ($101 billion) takeover approach was rejected. Pfizer shares on the Dow Jones Industrial Average rose 2 percent on Monday in the U.S. AstraZeneca refused to comment on the speculation when contacted by CNBC. On Monday, shares of AstraZeneca plc (ADR) (NYSE:AZN) advanced 8.84% to close the day at $69.10. Company return on investment (ROI) is 9.00% and its monthly performance is recorded as 6.55%. AstraZeneca plc (ADR) (NYSE:AZN) quarterly revenue growth is 11.54%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone